Allergan Inc., USA
Ruiwen Shi holds a Ph.D. in Pharmaceutics from the University of British Columbia and is currently a principal scientist in Allergan. He has been working in the field of local drug delivery for more than 15 years. His work in Allergan is centered around developing novel long-acting intraocular drug delivery systems for treating both front and back of the eye diseases. Prior to Allergan, he worked for Alza Corporation, Bausch + Lomb, and Mannkind Corporation and made contributions to the development of the intravitreal implant Retisert® and the rapid-acting inhaled insulin Afrezza®. Ruiwen has been very passionate about drug delivery systems and was the chair of the Ocular Drug Delivery Focus Group of the Controlled Release Society.
Oligonucleotides, peptides and proteins remain a significant challenge for sustained or controlled delivery. Many of these agents have been clinically validated in ophthalmology with great success as exemplified by Macugen®, Eylea® and Lucentis®. However, there remains a critical unmet medical need to sustain or target the delivery of these agents. The clinical application of macromolecule drug substances is limited due to poor bioavailability and disposition. Direct intravitreal administration of these agents mitigates the issues of poor bioavailability, however short half‐lives relative to duration of therapy results in a requirement for frequent high dose administrations. Current strategies and recent advances for the sustained delivery of macromolecules will be reviewed. Intravitreal delivery considerations for these agents not only includes sustained release, but also enhancing cellular their therapeutic profile. Prevention of aggregation and degradation in addition to sustained release are keys to enabling local delivery of these agents. In this presentation advances in the delivery of these therapeutic agents will be reviewed.